Life Scientist > Lab Technology

Love-ins and protests over, it's down to work for new Qld precinct

22 May, 2003 by Pete Young

The newest superstar among Australian life science research centres, the Queensland Bioscience Precinct, is getting down to business after an official opening that was part love-in, part confrontation.


Xcelerator appointment sets stage for push into Asia

22 May, 2003 by Jeremy Torr

Sydney based biotech incubator Xcelerator has beefed up its board with an old Asia hand in the form of ex-Johnson & Johnson chairman Michael Yates.


IATIA will use Bio-Rad partnership to focus on AP

22 May, 2003 by Jeremy Torr

A recent deal with Bio-Rad Asia-Pacific has seen Melbourne bio-optical equipment makers IATIA expand sales into an impressive 17 countries throughout the region.


Gradipore still filtering applicants for top job

22 May, 2003 by Jeremy Torr

Time is not on Gradipore's side. Not only has its separation technology been delayed by production problems, but it still hasn't found a replacement CEO for the trouble-shooting Bob Lieb, who officially departs at the end of this week.


Federal science spending hits new heights

19 May, 2003 by Simon Grose

The federal government is showing no signs of backing away from its Backing Australia's Ability program -- and there could be more good news to come.


Melbourne industry group launches strategy

08 May, 2003 by Melissa Trudinger

Recently-formed alliance The BioMelbourne Network has unveiled its action agenda for driving the Victorian biotechnology sector forward, focusing on building networks between science, government and business, and promoting Melbourne as a regional hub for the industry.


NSW companies dominate fourth-round BIF funding

01 May, 2003 by Pete Young

More than 40 organisations -- nearly half of them in NSW -- will share nearly $AUD10 million from the fourth round of the federal government's Biotechnology Innnovation Fund (BIF) grants announced today.


Researchers explore biosensor applications for fluorescence discovery

28 April, 2003 by Melissa Trudinger

A coral protein with an intense blue colour has properties that could prove useful as a biological probe to track interactions between proteins and cells, according to new research from Monash and Queensland universities.


Making IT headlines

28 April, 2003 by Eve Epstein

Bob Palermini got his first taste of Unix some 25 years ago when he became involved in production at a small newspaper that used the system to set type. Although he started out as an editor, Palermini was hooked on IT after that initial experience and taught himself the skills to make the transition to the technology side of the business. “Early on it was trial and error and books,” he says.


The ones to watch

24 April, 2003 by Melissa Trudinger

Melissa Trudinger takes a look at the emerging biotech clusters in Perth and Adelaide.


Value of deals overrated: KPMG

23 April, 2003 by Melissa Trudinger

Doing deals is one of the cornerstones of biotechnology, and can cover a myriad of activities from obtaining private or public equity, to collaborations and joint ventures, and in- and out-licensing of technology and products. But while transactions can increase the value of a company, too often the deal itself can lead to a decline in shareholder value.


Eiffel wooed by US VC agents

22 April, 2003 by Jeremy Torr

In what it hopes is the first step towards a Nasdaq listing, Melbourne platform technology biotech Eiffel Technologies has appointed New York-based introduction agents Global Markets Capital Corporation (GMCC) to represent it on the US investor market.


Optiscan reveals tough new strategy

16 April, 2003 by Pete Young

Listed biotech Optiscan Imaging, one of many struggling to conserve cash while waiting for their IP to reach commercial fruition, appears to have won some breathing space with a tough new strategy.


Opposition grows in face of PIIP axing rumours

16 April, 2003 by Jeremy Torr

Industry protests are coming loud and long following reports that the federal government's PIIP (Pharmaceutical Investment Incentive Scheme) may be axed in the next budget.


Euro-demand for Corbett range

15 April, 2003 by Jeremy Torr

Australian-based research instrument specialist Corbett Research has sealed a hardware deal with prime Swedish genetic analysis company Pyrosequencing.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd